$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

The objective of this study was to investigate the effects of sodium lauryl sulfate upon the saturation solubility of carbamazepine, its dissolution kinetics, and $T_{50\%}$ defined as the time required for dissolving $50\%$ of carbamazepine. Water, 0.1N-HCI, and phosphate buffers at pH 4.0 and 6.8 containing 0.1, 0.5, 1, and $2\%$ sodium lauryl sulfate were used as dissolution media. The dissolution study was conducted by using the USP dissolution apparatus II with an agitation rate of 75 rpm. Samples of the dissolution media were taken in 7, 15, 30, 45, 60, 75, and 90 min, and the amounts of carbamazepine were determined spectrophotometrically at 285 nm. All dissolution data were fitted well into a four-parameter exponential equation: $Q\;=\;a(1\;-\;e^{-bxt})\;+\;c(1\;-\;e^{-dxt})$. In this equation Q represented $\%$ carbamazepine dissolved at a time t, and a, b, c, and d were constants. This equation led to the calculation of dissolution rates at various time points and $T_{50\%}$. It was found that the dissolution rate of carbamazepine was directly proportional to the aqueous concentration of sodium lauryl sulfate. In addition, under our experimental conditions $T_{50%}$ values ranged from 37.8 to 4.9 min. It was interesting to note that $T_{50\%}$ declined rapidly as the surfactant concentration increased from 0.1 to $0.5\%$, whereas it declined more slowly at concentrations greater than $1\%$. These results clearly demonstrated that the dissolution rate of carbamazepine and duration of its dissolution test could be tailored by optimizing the amount of sodium lauryl sulfate in a dissolution medium.

참고문헌 (20)

  1. Aunins, J. G., Southard, M., Meyers, R. A., Hemmelstein, K. J., and Stella, V. J., Dissolution of carboxylic acids III. The effect of polyionizable buffers. J. Pharm. Sci., 74, 1305-1316 (1985) 
  2. Castillo, J. A., Palomo-Canales, J., Garcia, J. J., Lastres, J. L., Bolas, F., and Torrado, J. J., Preparation and characterization of albendazole ${\beta}$-cyclodextrin complexes. Drug Dev. Ind. Pharm., 25, 1241-1248 (1999) 
  3. FDA, Center for Drug Evaluation and Research. Guidance for Industry - SUPAC-MR: Modified release solid oral dosage forms: Scale-up and postapproval changes: Chemistry, manufacturing, and controls; in vitro dissolution testing and in vivo bioequivalence documentation, September 1997a 
  4. Jain, A. C. and Adeyeye, M. C., Hygroscopicity, phase solubility and dissolution of various substituted sulfobutylether ${\beta}$- cyclodextrins (SBE) and danazol-SBE inclusion complexes. Int. J. Pharm., 212, 177-186 (2001) 
  5. Langernbucher, F., Linearization of dissolution rate curves by the Weibull distribution. J. Pharm. Pharmacol., 24, 979-981 (1972) 
  6. Serajuddin, A. T. and Rosoff, M., pH-solubility profile of papaverine hydrochloride and its relationship to the dissolution rate of sustained-release pellets. J. Pharm. Sci., 73, 1203-1208 (1984) 
  7. Qazi, S., Peter Samuel, N. K., Venkatachalam, T. K., and Uckun, F. M., Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. Int. J. Pharm., 252, 27-39 (2003) 
  8. Costa, P. and Lobo, J. M. S., Influence of dissolution medium agitation on release profiles of sustained-release tablets. Drug Dev. Ind. Pharm., 27, 811-817 (2001) 
  9. Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., and Skelly, J. P., In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm. Res., 6, 612-618 (1989) 
  10. Abrahamsson, B., Johansson, D., Torstensson, A., and Wingstrand, K., Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine. Pharm. Res., 11, 1093-1097 (1994) 
  11. Dawoodbhai, S. et al., Optimization of tablet formulation talc. Drug Dev. Ind. Pharm., 17, 1343-1371 (1991) 
  12. FDA, Center for Drug Evaluation and Research. Guidance for Industry - Immediate release solid dosage forms: Scale-up and postapproval changes (SUPAC-IR): Chemistry, manufacturing, and controls, in vitro dissolution testing and in vivo bioequivalence test documentation, November, 1995 
  13. FDA, Center for Drug Evaluation and Research. Guidance for Industry - Extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlation, September 1997b 
  14. Sun, W., Larive, C. K., and Southard, M. Z., A mechanistic study of danazol dissolution in ionic surfactant solutions. J. Pharm. Sci., 92, 424-435 (2003) 
  15. Crison, J. R., Weiner, N. D., and Amidon, G. L., Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J. Pharm. Sci., 86, 384-388 (1997) 
  16. Chen, L. R., Wesley, J. A., Bhattachar, S., Ruiz, B., Bahash, K., and Babu, S. R., Dissolution behavior of a poorly water soluble compound in the presence of Tween 80. Pharm. Res., 20, 797-801 (2003) 
  17. Riegelman, S. and Collier, P., The application of statistical moment theory to the evaluation of the in vivo dissolution time and absorption time. J. Pharmacokient. Biopharm., 8, 509-534 (1980) 
  18. Pena Romero, A. et al., Water uptake and force development in an optimized prolonged release formulation. Int. J. Pharm., 73, 239-248 (1991) 
  19. Kervinen, L. and Yliruusi, J., Modelling S-shaped dissolution curves. Int. J. Pharm., 92, 115-122 (1993) 
  20. Velasco-De-Paola, M. V. R., Santoro, M. I. R. M., and Gai, M. N., Dissolution kinetics evaluation of controlled-release tablets containing propranolol hydrochloride. Drug Dev. Ind. Pharm., 25, 535-541 (1999) 

이 논문을 인용한 문헌 (1)

  1. 2011. "" Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea, 34(11): 1973~1982 

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일